Distinct NSCLC EGFR Variants in a Family With Li-Fraumeni Syndrome: Case Report [0.03%]
家族性李-弗拉门尼综合征肺癌患者的EGFR新突变病理报告
Shelby Edmondson,Mitchell S von Itzstein,Brian Reys et al.
Shelby Edmondson et al.
Introduction: Heritable lung cancer may occur in the context of germline TP53 mutations (Li-Fraumeni syndrome). Limited cases of intrafamily tumor genomic characteristics have been reported. ...
Radiation-Induced Peripheral Neuropathy After Thoracic Stereotactic Ablative Radiotherapy: Case Report [0.03%]
胸部立体定向消融放射治疗后由放疗引起的外周神经病变：病例报告
Ha H Pham,Neil Newman,Evan C Osmundson
Ha H Pham
Stereotactic ablative radiotherapy (SABR) is a highly effective treatment for medically inoperable patients with early stage NSCLC. Because of its noninvasive nature and favorable toxicity profile, the use of SABR continues to expand for el...
Brief Report: Contralateral Lobectomy for Second Primary NSCLC: Perioperative and Long-Term Outcomes [0.03%]
短篇报告：第二原发NSCLC的对侧肺叶切除术：围手术期和长期结局
Jennie K Choe,Amy Zhu,Alexander J Byun et al.
Jennie K Choe et al.
Introduction: Anatomical resection-often by lobectomy-is the standard of care for patients with early stage NSCLC. With increased diagnosis, survival, and prevalence of persons with early stage NSCLC, the incidence of sec...
A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib [0.03%]
Lorlatinib治疗ROS1重排脑部进展性肺癌的临床试验
Jaime L Schneider,Alona Muzikansky,Jessica J Lin et al.
Jaime L Schneider et al.
Introduction: The central nervous system (CNS) is a common site of progression among patients with ROS1-rearranged lung cancer receiving crizotinib. We conducted a phase 2 study to evaluate the intracranial efficacy of lo...
Logan Roof,Wei Wei,Katherine Tullio et al.
Logan Roof et al.
Objectives: To determine how the incidence and demographics of SCLC have changed over time and to evaluate whether patient demographics, disease presentation, and treatment characteristics affect patient outcomes. ...
Brief Report: Implementation of a Universal Prescreening Protocol to Increase Recruitment to Lung Cancer Studies at a Veterans Affairs Cancer Center [0.03%]
简报：在退伍军人事务癌症中心实施一种普遍的预筛查协议以增加肺癌研究的招募人数
Jenny J Xiang,Alicia Roy,Christine Summers et al.
Jenny J Xiang et al.
Introduction: The oncology clinical trial recruitment process is time, labor, and resource intensive, and poor accrual rates are common. We describe the VA Connecticut Cancer Center experience of implementing a standardiz...
National Cancer Institute Smoking Cessation at Lung Examination Trials Brief Report: Baseline Characteristics and Comparison With the U.S. General Population of Lung Cancer Screening-Eligible Patients [0.03%]
肺癌筛查合格患者的人口统计特征及与美国普通人群的比较：国立癌症研究所肺癌筛查中的戒烟试验简报
Rafael Meza,Jihyoun Jeon,Evelyn Jimenez-Mendoza et al.
Rafael Meza et al.
Introduction: The National Cancer Institute Smoking Cessation at Lung Examination (SCALE) Collaboration includes eight clinical trials testing smoking cessation interventions delivered with lung cancer screening (LCS). Th...
A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC [0.03%]
新辅助帕博利珠单抗联合放化疗后以帕博利珠单抗巩固治疗可切除III期NSCLC患者的I期研究
Christopher A Lemmon,Gregory M M Videtic,Sudish Murthy et al.
Christopher A Lemmon et al.
Introduction: Evidence supports the addition of immunotherapy to definitive chemoradiation for unresectable stage IIIA NSCLC. Adding pembrolizumab to neoadjuvant chemoradiation in patients with resectable stage IIIA NSCLC...
Bilateral Pleural Mesothelioma In Situ and Peritoneal Mesothelioma In Situ Associated With BAP1 Germline Mutation: A Case Report [0.03%]
与BAP1胚系突变相关的双侧胸膜原位间皮瘤和腹膜原位间皮瘤：病例报告
Alyssa MacLean,Andrew Churg,Scott Thomas Johnson
Alyssa MacLean
Mesothelioma in situ is a recently described precursor to invasive mesothelioma. Thus far, all cases in the literature have involved one pleural cavity or the peritoneal cavity. We describe a patient with biopsy-proven mesothelioma in situ ...
Two Uncomplicated Pregnancies on Alectinib in a Woman With Metastatic ALK-Rearranged NSCLC: A Case Report [0.03%]
阿莱替尼治疗转移性间变淋巴瘤激酶重排型非小细胞肺癌期间发生两次单纯妊娠：个案报告
Chloe Weidenbaum,Christopher G Cann,Sarah Osmundson et al.
Chloe Weidenbaum et al.
Lung cancer incidence is increasing in pregnancy due in part to advanced maternal age. A subset of patients with NSCLC during pregnancy harbor an ALK gene rearrangement. Although ALK inhibitors, such as alectinib, are routinely used to trea...